News | August 09, 2022
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Strides is the first Indian company to get approval for the product.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Subscribe To Our Newsletter & Stay Updated
